PatientsVille.com Logo

WEIGHT INCREASED and Plavix

PatientsVille

WEIGHT INCREASED Symptoms and Causes

Do you know if your current weight is healthy? "Underweight", "normal", "overweight", and "obese" are all labels for ranges of weight. Obese and overweight mean that your weight is greater than it should be for your health. Underweight means that it is lower than it should be for your health. Your healthy body weight depends on your sex and height. For children, it also depends on your age.

A sudden, unexpected change in weight can be a sign of a medical problem. Causes for sudden weight loss can include

  • Thyroid problems
  • Cancer
  • Infectious diseases
  • Digestive diseases
  • Certain medicines

Sudden weight gain can be due to medicines, thyroid problems, heart failure, and kidney disease.

Good nutrition and exercise can help in losing weight. Eating extra calories within a well-balanced diet and treating any underlying medical problems can help to add weight.

Check out the latest treatments for WEIGHT INCREASED

WEIGHT INCREASED treatment research studies

Plavix clinical trials, surveys and public health registries


Find Drug Side Effect reports



Plavix Side Effects

Myocardial Infarction (302)
Dyspnoea (270)
Anaemia (263)
Contusion (260)
Asthenia (251)
Death (238)
Cerebrovascular Accident (215)
Gastrointestinal Haemorrhage (207)
Dizziness (204)
Chest Pain (200)
Haemorrhage (176)
Fall (166)
Fatigue (162)
Headache (152)
Haemoglobin Decreased (145)
Diarrhoea (137)
Nausea (132)
Epistaxis (132)
Pruritus (129)
Coronary Artery Occlusion (123)
Pain (117)
Pyrexia (116)
Malaise (112)
Loss Of Consciousness (109)
Rash (108)
Rectal Haemorrhage (106)
Pain In Extremity (105)
Transient Ischaemic Attack (104)
Off Label Use (100)
Weight Decreased (98)
Atrial Fibrillation (98)
Melaena (96)
Arthralgia (93)
International Normalised Ratio Increased (91)
Haematemesis (90)
Abdominal Pain Upper (90)
Pneumonia (89)
Condition Aggravated (89)
Cardiac Failure Congestive (87)
Oedema Peripheral (87)
Renal Failure (85)
Vomiting (85)
Hypertension (85)
Angina Pectoris (85)
Hypotension (84)
Back Pain (83)
Confusional State (81)
Thrombosis (81)
Gait Disturbance (73)
Myalgia (72)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

75 mg

A horrible experience taking plavix, i had all the side effects taking this drug ,question ur Dc. before taking it and 9don,t believe him)

About a year ago i had a stroke also bad dry skin,i also had a full head of hair and a full beard lately my beard and hair are both are both falling out

Could plavix be the reason for my hair loss

Deadly stay away

Gastrointestinal. Severe pain starting in middle of chest and wrapping around to middle of back. Tests showed inflamation in stomach and I am now on a bland diet indefinately. Also had trouble swallowing pills and food.&

I AM HAVING HAIR LOSS AND I AM NOT TAKING PLAVIX

I have been on plavix and asparin 4 months, SP cerebral aneurysm repair) this evening I fell hard on my low back(completely missed a chair ), i couldnt move for a few mins, really hurt... got up, applied ice to low back,moving ok but sore, I guess I

I was placed on plavix after a pfo closure surgery. I have felt depressed and have experienced crying spells. Its very unlike my personality. The more people I talk to the more common it seems to be a serious issue.

In 2001 I had heart attack and I was found to have 3 major blockages in my heart arteries.I was offered three choices ie. medication ,stent,or bypass surgery.I opted for a stent and i was put on medication ie. plavix 75mg,caprin 75mg,.lipos

Weight gain of 25 lbs. Normally weigh 120. Os tjos possible

<b><span style='font-weight: normal;'><b>After 6 weeks of oral lamisil I experienced</b>eczema, muscle weakness, asthma, bloody bowels, lower abdominal pain, dizziness, extreme f

I have been put on Molipaxin 3 weeks ago, I have dry mouth, hair loss and my panic attacks were showing no signs of improvement. Dr increased it to 100mg and put me onto Lamictin. I am not bi polar nor epileptic. My disorder ist algora phoebia. I a

I have just come back from a funeral for my brother. He was just 62. He was on statin medicine but his cholestrol, blood pressure, weight and diet was very much in control. In fact just a day before his death the doctor told him that he was doing f

Side effects I have from Nadolol are confusion, dizziness, lightheaded, increased depression and anxiety, and mild nausea.

Has anyone gained weight from taking xyzal? It has helped my alergies but I've gained 12 lbs.....

Have taken hydrea for a year because my spleen had increased in size. I have noticed increased loss of memory and some confusion for the past couple of months. I take 500 mg every other day and 1000 mg every other day.

I don't know. I have been taking Lithium for my Bi-Polar for three years now, and besides the weight gain, I have been doing well! My Doctor wants me to try Zeldox, what should I do?

I have experienced weight loss of a pound a month for the last 2 years, since taking 100 mcg per day. My dr. can find no cause for this loss. I also have taken Metformin for about the same amount of time.

On 4/25/2006, I took the first of the three Hepatitis B shots. I suddenly had flu like symptoms which lasted for ever. I started getting really weak. I would eventually start losing weight. I went from 269 down to 118. I was diagnosed with Dermatomy

WEIGHT INCREASED Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS
Condition: CLOPIDOGREL, POOR METABOLISM of (Disorder)
Interventions: Drug: genotyping guided therapy Ticagrelor, Clopidogrel;   Drug: standard therapy clopidogrel
Outcome Measure: Clopidogrel response status as measured by the LTA assay in CYP2C19*2 carriers.
2 Recruiting Comparative Pharmacodynamics and Pharmacokinetics Study of Generic and Reference Clopidogrel Products
Condition: Antiplatelet Agents
Interventions: Drug: Generic clopidogrel product Apolets®;   Drug: Original clopidogrel product Plavix®
Outcome Measures: Pharmacodynamic effect: The platelet inhibition effect of clopidogrel at the various times on day 7 (0-24 hours) (at steady state);   Pharmacokinetic profiles: Area Under the Concentration-Time Curve (AUC 0-24);   Pharmacokinetic profiles: The Maximum Plasma Concentration (Cmax);   Pharmacokinetic profiles: Time to Maximum Plasma Concentration (Tmax)
3 Recruiting Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy
Conditions: Diabetes Type 2;   Diabetic Nephropathy;   Vascular Disease
Interventions: Drug: Ramipril;   Drug: Clopidogrel
Outcome Measures: Changes in Asymmetric dimethylarginine (ADMA) blood levels after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy;   Changes in High-sensitivity C-reactive protein (HsCRP) blood levels after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy;   Changes in soluble CD40 Ligand (sCD40L)blood levels after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy;   Changes in urine 8-isoprostane-F2 levels after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy;   Reduction in albumine to creatine ratio after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy;   Changes in ADMA blood levels after treatment with ramipril;   Increase of Glomerular Filtration Rate (GFR) after combined treatment with ramipril and clopidogrel and after ramipril monotherapy;   Change from baseline in carotid intima-media thickness after combined therapy with ramipril and clopidogrel and after ramipril monotherapy
4 Recruiting Aspirin and Plavix Following Coronary Artery Bypass Grafting
Condition: Coronary Graft Patency
Interventions: Drug: clopidogrel;   Drug: sugar pill
Outcome Measures: Incidence of more than 50% stenosis in graft with combination therapy with aspirin and clopidogrel vs. aspirin alone;   Incidence of bleeding between the two treatment arms;   Percent change major adverse cardiovascular events (angina, any thrombotic events, and myocardial infarction) with combination therapy with aspirin and clopidogrel vs. aspirin alone
5 Not yet recruiting Optimal Anti-platelet Treatment for Patients With Clopidogrel Low Response
Condition: Coronary Artery Disease
Interventions: Drug: Ticagrelor;   Drug: Clopidogrel;   Drug: Cilostazol
Outcome Measures: Inhibition of platelet aggregation (IPA);   Clinical efficacy
6 Recruiting Effectiveness of Clopidogrel Resinate in PCI(PRIDE)
Condition: Coronary Artery Disease
Interventions: Drug: Pregrel®;   Drug: Plavix®
Outcome Measures: composite of death (all cause-mortality), MI (Q wave and non Q wave) and stroke;   composite of death, MI, stroke, or urgent revascularization;   Individual components of death, MI, stroke, or urgent revascularization;   The need for target vessel revascularization or any revascularization;   The incidence of early discontinuation of study drugs;   The incidence of major bleeding events;   Stent thrombosis
7 Not yet recruiting Clopidogrel Resistance and Embolism in Carotid Artery Stenting
Condition: Carotid Stenosis
Interventions: Drug: Ticlopidine + Ginko biloba;   Drug: Clopidogrel
Outcome Measures: New ischemic lesion on diffusion-weighted imaging (DWI);   Number and Volume of new ischemic lesions on DWI;   Benign and malignant microembolic signals (MES) on transcranial Doppler (TCD);   Ischemic stroke or transient ischemic attack (TIA);   Change of clopidogrel resistance;   Pucture site hematoma;   Mycocardial infarction;   Death;   Hematological abnormalities
8 Recruiting Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention
Condition: Acute Coronary Syndrome
Interventions: Drug: Prasugrel;   Drug: Clopidogrel
Outcome Measures: HPR at 24 hours;   MACE;   Bleeding;   HPRs
9 Recruiting Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?
Condition: Clopidogrel
Interventions: Drug: Clopidogrel;   Drug: Discontinue Clopidogrel
Outcome Measures: Perioperative Bleeding Complications;   Development of myocardial infarction or thrombosis
10 Unknown  Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance
Condition: Acute ST SEgment Elevation Myocardial Infarction
Interventions: Drug: Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG;   Drug: Aspirin 100mg and Plavix 75mg
Outcome Measures: To determine usefulness of thromboelastography (TEG) as a valuable tool in assessing platelet response to clopidogrel treatment and post-treatment platelet reactivity during acute ST segment elevation myocardial infarction (STEMI).;   To determine the correlation between platelet response to clopidogrel treatment and the outcome of patients who underwent percutaneous coronary intervention (PCI) for STEMI.
11 Recruiting Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients
Condition: Coronary Artery Disease
Interventions: Drug: Ticagrelor;   Drug: Clopidogrel
Outcome Measures: Compare ticagrelor's versus clopidogrel's inhibition of the P2Y12 receptor as measured by the decrease in P2Y12 Reaction Units (PRU) using VerifyNow TM.;   Compare the decrease of P2Y12 Reaction Units (PRU) by VerifyNow TM from ticagrelor and clopidogrel.;   Compare the decrease in P2Y l2 Reaction Units (PRU) by VerifyNow™ from ticagrelor's and clopidogrel's morning dose on Day 7;   To evaluate and compare the pharmacodynamic effects, measured by the vasodilator-stimulated phosphoprotein (VASP) assay (platelet reactivity index [PRI]), in all subjects;   Assess and to compare the percentage of subjects with High on-treatment Platelet Reactivity (HPR) at all time points after randomized study treatment.
12 Recruiting Evaluation of the Biological Response to Clopidogrel in Patients With Ischemic Stroke
Conditions: Brain Ischemia;   Ischemic Attack
Intervention: Drug: Clopidogrel
Outcome Measures: adrenergic component of the platelet response;   VASP-CMF;   ELISA VASP;   active metabolite of clopidogrel;   Genotyping of MDR-1 and P450 2C19
13 Recruiting Transition From Ticagrelor to Clopidogrel Following Acute Coronary Syndrome: To Bolus or Not?
Condition: Acute Coronary Syndrome
Intervention: Drug: Clopidogrel
Outcome Measures: Platelet inhibition as assessed by P2Y12 reaction Unit (PRU) after transition from Ticagrelor to Clopidogrel.;   The difference in platelet inhibition (as expresses as PRU) between the two groups at specified time points.
14 Recruiting Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding
Condition: Gastrointestinal Bleeding
Intervention: Drug: clopidogrel
Outcome Measures: Delayed post-polypectomy bleeding;   Immediate post-polypectomy bleeding
15 Not yet recruiting Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis
Conditions: Acute ST Segment Elevation Myocardial Infarction;   Acute Coronary Syndrome
Interventions: Drug: Ticagrelor;   Drug: Clopidogrel
Outcome Measures: Pharmacodynamics (PRU and IPA) of ticagrelor vs Clopidogrel using VASP and VerifyNow;   Pharmacokinetic (AUC, Cmax, Tmax)
16 Unknown  Plavix, Prasugrel and Drug Eluting Stents Pilot Trial
Conditions: Coronary Artery Disease;   Platelet Aggregation Inhibitors;   PCI- Percutaneous Coronary Intervention
Interventions: Drug: Loading Dose Arm;   Drug: Maintenance Dose Arm
Outcome Measures: Change in platelet reactivity after switching medication regimen of two thienopyridines- clopidogrel and prasugrel;   Occurrence of all bleeding events for subjects enrolled into the trial;   Occurrence of all MACE events for subjects enrolled into the trial
17 Unknown  Clopidogrel Reloading in Patients With NSTEACS Undergoing Percutaneous Coronary Intervention on Chronic Clopidogrel Therapy
Conditions: Acute Coronary Syndrome;   Myocardial Infarction
Interventions: Drug: Clopidogrel;   Drug: Placebo
Outcome Measures: Major Adverse Cardiovascular Events;   Bleeding Events;   Grade of platelet residual reactivity
18 Not yet recruiting Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel
Conditions: Diabetes Mellitus;   Coronary Disease
Interventions: Drug: Ticagrelor;   Drug: Continued clopidogrel
Outcome Measures: Rate of elevation of troponin or CK-MB (above the upper limit of normal, and above 3 times the upper limit of normal) measured 20-24 hours after the PCI.;   Rate of major adverse cardiovascular endpoints including death, myocardial infarction or urgent target vessel revascularization at 30 days
19 Recruiting Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients
Conditions: Type-2 Diabetes Mellitus;   Coronary Artery Disease
Interventions: Drug: Ticagrelor + Aspirin;   Drug: Clopidogrel + Aspirin
Outcome Measures: Thrombus formation;   Platelet reactivity;   Vasodilator-Stimulated Phosphoprotein phosphorylation assay
20 Unknown  Pharmacogenomics and Effective Treatment With Clopidogrel
Condition: Pharmacogenomics
Intervention: Genetic: Pharmacogenomics
Outcome Measure: